birtamimab: Clinical Trials

7 trials of birtamimab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 terminated, 2 completed. 5 Phase 2, 2 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Terminated 3, Completed 2
Phase 32Terminated 2
Phase 11Completed 1

Follow birtamimab: new trials by email Literature Review of birtamimab trials Research Report on birtamimab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis
Birtamimab, Placebo, Standard of Care Chemotherapy - Light Chain (AL) Amyloidosis
Phase 3TerminatedProthena Biosciences Ltd.2082021-08-302025-12-16
Renal AL Amyloid Involvement and NEOD001
NEOD001, Placebo - Amyloidosis
Phase 2TerminatedTufts Medical Center122017-07-052020-09-09
Study in Subjects With Light Chain (AL) Amyloidosis
NEOD001 - AL Amyloidosis
Phase 2TerminatedProthena Biosciences Ltd.802017-06-142019-03-26
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
NEOD001, Placebo - AL Amyloidosis
Phase 2CompletedProthena Biosciences Ltd.1292016-03-012019-04-05
Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
NEOD001 - AL Amyloidosis
Phase 2TerminatedProthena Biosciences Ltd.342016-02-012019-05-16
The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis
NEOD001, Placebo - Primary Systemic (AL) Amyloidosis
Phase 3TerminatedProthena Biosciences Ltd.2602015-02-012023-11-14
Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
NEOD001 - Primary Amyloidosis
Phase 1 / Phase 2CompletedProthena Biosciences Ltd.692013-04-012018-08-28

Conditions studied

Immunoglobulin Light-chain Amyloidosis (5)  ·  Amyloidosis (3)  ·  Alzheimer Disease (1)  ·  Paraproteinemias (1)

Sponsors

Prothena Biosciences Ltd. (6)  ·  Tufts Medical Center (1)

Countries

United States (7)  ·  Australia (4)  ·  Austria (4)  ·  France (4)  ·  Germany (4)  ·  Greece (4)  ·  Israel (4)  ·  Italy (4)  ·  Spain (4)  ·  United Kingdom (4)  ·  Belgium (2)  ·  Canada (2)  ·  Denmark (2)  ·  Netherlands (2)  ·  Poland (2)

Top investigators

Julia Martinisi (1)  ·  Raymond Comenzo, MD (1)

Results publications

PMID 37366170, PMID 26858336, PMID 38600883